Prognosis of patients with small cell lung cancer with or without interstitial pneumonia treated with postoperative adjuvant chemotherapy: A retrospective study

Prognosis of patients with small cell lung carcinoma with or without interstitial pneumonia treated with postoperative adjuvant chemotherapy: A retrospective study - Prognosis of patients with SCLC with or without IP treated with postoperative adjuvant chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051612

Enrollment

Registered

2023-07-15

Start date

2023-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Treated with surgery and adjuvant chemotherapy for small cell lung cancer. 2. Chemotherapy was started between April 1, 2011, and September 30, 2021. 3. patients who received platinum agent plus etoposide as postoperative chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Patient who received chemoradiotherapy as postoperative treatment. 2. Patient who had not been treated with postoperative adjuvant chemotherapy.

Design outcomes

Primary

Measure	Time frame
The 3-year overall survival rate	—

Secondary

Measure	Time frame
3-year disease-free survival rate, overall survival, disease-free survival, frequency of adverse events, frequency and severity of treatment-related acute exacerbations of interstitial pneumonia.	—

Countries

Japan

Contacts

Public ContactMikihito Saito

Chiba University Hospital Department of Respirology

saitomikihito@chiba-u.jp043-222-7171

Outcome results